Torrent Pharma Q2 Review - Better Show In India, Brazil Offset By Weak U.S. Sales: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.Torrent Pharmaceutical Ltd.’s operational performance in Q2 FY22 was slightly below our expectations. The growth momentum in the domestic formulation and Brazil businesses was offset by a muted show in the U.S. business and a higher tax rate. A recovery in the U.S. business remains contingent upon regulatory compliance at its key sites.The company remains on track to outperform in the branded generics market of India/Latin America. Torrent Pharma’s plan to make inroads into the trade generics segment will create further growth opportunities in the domestic formulation segment. However, the company’s overall return ratios could remain suppressed until its U.S. generic business continues to be impacted by regulatory hurdles..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Torrent Pharma Q2 Review - Better Show In India, Brazil Offset By Weak U.S. Sales: Motilal Oswal

Torrent Pharma Q2 Review - Better Show In India, Brazil Offset By Weak U.S. Sales: Motilal Oswal

Choose a plan